Company profile for CRISPR Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

At CRISPR Therapeutics, we are focused on developing transformative gene-based medicines for serious human diseases. We are rapidly translating our specific, efficient and versatile CRISPR/Cas9 gene-editing platform into therapies to treat hemoglobinopathies, cancer, diabetes and other diseases. Our multi-disciplinary team of world-class researchers and drug developers works every day to translate our CRISPR/Cas9 technology in...
At CRISPR Therapeutics, we are focused on developing transformative gene-based medicines for serious human diseases. We are rapidly translating our specific, efficient and versatile CRISPR/Cas9 gene-editing platform into therapies to treat hemoglobinopathies, cancer, diabetes and other diseases. Our multi-disciplinary team of world-class researchers and drug developers works every day to translate our CRISPR/Cas9 technology into breakthrough human therapeutics. Our lead program targeting the blood diseases β-thalassemia and sickle cell disease has entered clinical testing.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
610 Main Street (enter on Portland Street), Cambridge, MA 02139
Telephone
Telephone
617-315-4600
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

DCAT Week

DCAT Week

Not Confirmed

envelop Contact Supplier

DCAT Week

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/11/10/3184507/0/en/CRISPR-Therapeutics-Provides-Business-Update-and-Reports-Third-Quarter-2025-Financial-Results.html

GLOBENEWSWIRE
10 Nov 2025

https://www.globenewswire.com/news-release/2025/11/08/3184062/0/en/CRISPR-Therapeutics-Announces-Positive-Phase-1-Clinical-Data-for-CTX310-Demonstrating-Deep-and-Durable-ANGPTL3-Editing-Triglyceride-and-Lipid-Lowering.html

GLOBENEWSWIRE
08 Nov 2025

https://www.globenewswire.com/news-release/2025/10/10/3164819/0/en/CRISPR-Therapeutics-Presents-New-Preclinical-Data-for-CTX460-Demonstrating-In-Vivo-Gene-Correction-of-Alpha-1-Antitrypsin-Deficiency-AATD-Utilizing-Novel-SyNTase-Editing-Platform.html

GLOBENEWSWIRE
10 Oct 2025

https://www.globenewswire.com/news-release/2025/10/01/3159436/0/en/CRISPR-Therapeutics-to-Present-Preclinical-Data-on-Alpha-1-Antitrypsin-Deficiency-AATD-Utilizing-Novel-SyNTase-Gene-Editing-Technology-at-the-European-Society-of-Gene-and-Cell-Ther.html

GLOBENEWSWIRE
01 Oct 2025

https://www.globenewswire.com/news-release/2025/09/22/3153917/0/en/CRISPR-Therapeutics-and-Sirius-Therapeutics-Announce-First-Patient-Dosed-in-Phase-2-Trial-of-SRSD107-for-Thromboembolic-Disorders-in-Europe.html

GLOBENEWSWIRE
22 Sep 2025

https://www.globenewswire.com/news-release/2025/09/09/3147319/0/en/CRISPR-Therapeutics-to-Present-Late-Breaking-Data-at-the-American-Heart-Association-AHA-Scientific-Sessions-2025.html

GLOBENEWSWIRE
09 Sep 2025

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty